SCR-7952
/ Simcere
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 23, 2024
SCR-7952, a highly selective MAT2A inhibitor, demonstrates synergistic antitumor activities in combination with the S-adenosylmethionine-competitive or the methylthioadenosine-cooperative protein arginine methyltransferase 5 inhibitors in methylthioadenosine phosphorylase-deleted tumors.
(PubMed, MedComm (2020))
- "Different from AG-270, SCR-7952 exhibited little influence on metabolic enzymes and did not increase the plasma levels of bilirubin. The mechanism was via the aggravated inhibition of PRMT5 and FANCA splicing perturbations. These results indicated that SCR-7952 could be a potential therapeutic candidate for the treatment of MTAP-deleted cancers, both monotherapy and in combination with PRMT5 inhibitors."
Combination therapy • Journal • Oncology • FANCA • MAT2A • MTAP
1 to 1
Of
1
Go to page
1